Older US adults' experiences with and views about cognitive screening and blood biomarker testing for Alzheimer's disease

被引:0
|
作者
Cox, Chelsea G. [1 ]
Kirch, Matthias [2 ]
Singer, Dianne [2 ]
Solway, Erica [2 ]
Malani, Preeti N. [3 ]
Kullgren, Jeffrey T. [2 ,3 ,4 ,5 ]
Roberts, J. Scott [1 ]
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Equ, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI USA
[3] Univ Michigan, Med sch, Dept Internal Med, Ann Arbor, MI USA
[4] Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA
[5] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI USA
关键词
Alzheimer's disease; biomarker testing; blood-based biomarkers; cognitive screening; dementia; early detection; ANNUAL WELLNESS VISIT; DEMENTIA; DIAGNOSIS; IMPAIRMENT; ATTITUDES;
D O I
10.1002/dad2.70067
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION Dementia is underdiagnosed in the United States. Understanding of older adults' experiences with screening is needed to optimize diagnosis. METHODS US adults ages 65 to 80 (N = 1298) were surveyed on experiences with cognitive screening and blood biomarker (BBM) testing. Regression models estimated associations between characteristics and screening use. RESULTS Most older adults were aware of screening (71%); 41% reported ever being screened. Older age, higher education, retirement, poorer health, and family history of dementia were associated with higher odds of screening; Hispanic and non-Hispanic Asian race/ethnicity were associated with lower odds (p < .05). Most older adults were unaware of BBM (81%); few wanted testing immediately (9%). Although older adults held positive views about screening and BBM, half reported concerns about distress or stigma if tests indicated risk. DISCUSSION Cognitive screening rates remain low. Older adults view screening and BBM as useful to inform health decisions but have concerns about potential harms. Highlights Only one in five older US adults report having cognitive screening in the past year. Sociodemographic and health factors may influence whether older adults receive cognitive screening. Most older adults have positive views about cognitive screening and BBM testing. Many older adults would be concerned about distress or stigma if test result indicated dementia risk.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Measuring Experiences of Discrimination in Older Adults Enrolled in an Alzheimer's Disease Research Cohort
    Patel, Nisha
    Halberstadter, Kimberly
    Schumann, Rosalie
    Mechanic-Hamilton, Dawn
    Stites, Shana D.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2023,
  • [22] Blood pressure variability and plasma Alzheimer’s disease biomarkers in older adults
    Isabel J. Sible
    Belinda Yew
    Jung Yun Jang
    John Paul M. Alitin
    Yanrong Li
    Aimée Gaubert
    Amy Nguyen
    Shubir Dutt
    Anna E. Blanken
    Jean K. Ho
    Anisa J. Marshall
    Arunima Kapoor
    Fatemah Shenasa
    Kathleen E. Rodgers
    Virginia E. Sturm
    Elizabeth Head
    Alessandra Martini
    Daniel A. Nation
    Scientific Reports, 12
  • [23] Blood pressure variability and plasma Alzheimer's disease biomarkers in older adults
    Sible, Isabel J.
    Yew, Belinda
    Jang, Jung Yun
    Alitin, John Paul M.
    Li, Yanrong
    Gaubert, Aimee
    Nguyen, Amy
    Dutt, Shubir
    Blanken, Anna E.
    Ho, Jean K.
    Marshall, Anisa J.
    Kapoor, Arunima
    Shenasa, Fatemah
    Rodgers, Kathleen E.
    Sturm, Virginia E.
    Head, Elizabeth
    Martini, Alessandra
    Nation, Daniel A.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [24] Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment
    Liu, Weilin
    Lin, Huawei
    He, Xiaojun
    Chen, Lewen
    Dai, Yaling
    Jia, Weiwei
    Xue, Xiehua
    Tao, Jing
    Chen, Lidian
    TRANSLATIONAL PSYCHIATRY, 2020, 10 (01)
  • [25] Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
    Weilin Liu
    Huawei Lin
    Xiaojun He
    Lewen Chen
    Yaling Dai
    Weiwei Jia
    Xiehua Xue
    Jing Tao
    Lidian Chen
    Translational Psychiatry, 10
  • [26] Polypharmacy in Older Adults with Alzheimer's Disease
    Esumi, Satoru
    Ushio, Soichiro
    Zamami, Yoshito
    MEDICINA-LITHUANIA, 2022, 58 (10):
  • [27] Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer's disease (from the Nakayama Study)
    Ozaki, Tomoki
    Yoshino, Yuta
    Tachibana, Ayumi
    Shimizu, Hideaki
    Mori, Takaaki
    Nakayama, Tomohiko
    Mawatari, Kazuaki
    Numata, Shusuke
    Iga, Jun-ichi
    Takahashi, Akira
    Ohmori, Tetsuro
    Ueno, Shu-ichi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [28] HETEROGENEOUS PREFERENCES FOR DELAYING ONSET OF ALZHEIMER'S DISEASE AMONG OLDER ADULTS IN THE US
    Reed, S. D.
    Yang, J.
    Disantostefano, R.
    Streffer, J.
    Levitan, B.
    Johnson, F. R.
    VALUE IN HEALTH, 2016, 19 (07) : A352 - A352
  • [29] Sleep in Older Adults With Alzheimer's Disease
    Song, Yeonsu
    Dowling, Glenna A.
    Wallhagen, Margaret I.
    Lee, Kathryn A.
    Strawbridge, William J.
    JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (04) : 190 - 198
  • [30] Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study)
    Tomoki Ozaki
    Yuta Yoshino
    Ayumi Tachibana
    Hideaki Shimizu
    Takaaki Mori
    Tomohiko Nakayama
    Kazuaki Mawatari
    Shusuke Numata
    Jun-ichi Iga
    Akira Takahashi
    Tetsuro Ohmori
    Shu-ichi Ueno
    Scientific Reports, 12